Eczema Research & Probiotic Solution

Overview: The Probiotic Revolution in Atopic Dermatitis

Atopic Dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin disease characterized by intense pruritus, disrupted skin barrier function, and immune dysregulation. While traditional treatments—corticosteroids, calcineurin inhibitors, and biologics—manage symptoms, they often come with side effects or fail to address the underlying microbial dysbiosis.

Recent breakthroughs in the Gut-Skin Axis have identified the microbiome as a critical lever in AD pathology. Research indicates that patients with eczema often exhibit reduced microbial diversity, specifically a depletion of beneficial Lactobacillus and Bifidobacterium strains and an overgrowth of Staphylococcus aureus. Probiotic interventions represent a paradigm shift. By restoring microbial balance, modulating the Th2-mediated immune response, and enhancing barrier integrity, live biotherapeutic products (LBPs) offer a potential disease-modifying strategy. As a specialized Contract Research Organization (CRO), Creative Biolabs is dedicated to accelerating your probiotic drug discovery from strain selection to preclinical proof-of-concept.

The benefits of probiotics for the skin. (Creative Biolabs Authorized)

Our Preclinical Technical Services

We offer a comprehensive suite of preclinical services tailored specifically for Live Biotherapeutic Products (LBPs) and Microbiome-Modulating Therapies in the context of Atopic Dermatitis.

In Vitro Screening & Mechanism Elucidation

Before animal testing, we validate your strains using high-throughput assays.

Immune Co-Culture Models: Co-culturing probiotics with PBMCs or Dendritic Cells to measure cytokine profiles (IL-10 vs. IL-4/IL-13 ratios).
Antimicrobial Assays: Zone of inhibition and competition assays against clinical S. aureus isolates.
Barrier Integrity Assays: Using Trans-Epithelial Electrical Resistance (TEER) on keratinocyte monolayers (e.g., HaCaT cells) to measure barrier strengthening properties.

In Vivo Efficacy Models (Atopic Dermatitis)

We utilize gold-standard murine models to test the therapeutic efficacy of oral or topical probiotics.

Chemically Induced Models (DNCB/Oxazolone): Induces AD-like skin lesions, elevated IgE, and barrier disruption. Ideal for testing anti-inflammatory efficacy.
Genetic Models (e.g., NC/Nga mice): Spontaneously develop AD-like symptoms under specific environmental conditions, closely mimicking human AD pathology.
Topical vs. Oral Administration Studies: Flexible dosing protocols to test gut-skin axis modulation (oral) or direct skin microbiome modulation (topical).

Multi-Omics & Readouts

Microbiome Sequencing: 16S rRNA gene sequencing to track colonization and microbiome shifts in the gut and skin.
Histopathology: H&E and Toluidine Blue staining to assess epidermal thickness and mast cell infiltration.
Immunological Profiling: ELISA and Flow Cytometry for serum IgE, tissue cytokines, and T-cell subpopulation analysis.

Mechanism of Action: How Probiotics Combat Eczema

To develop effective therapeutics, we must understand the distinct pathways by which probiotics exert their effects. Our research focuses on three core mechanisms:

1. Immune Modulation (The Systemic Effect):

Th1/Th2 Rebalancing: AD is driven by an overactive Th2 immune response. Probiotics can stimulate dendritic cells to produce IL-12 and IL-10, shifting the balance away from pro-inflammatory Th2 cytokines (IL-4, IL-5, IL-13) toward a regulatory phenotype.
Treg Induction: Specific strains induce Regulatory T cells (Tregs), which dampen systemic inflammation and reduce allergic sensitization.

2. Competitive Exclusion (The Antimicrobial Effect):

Pathogen Inhibition: Probiotics produce bacteriocins and organic acids that directly inhibit the colonization of Staphylococcus aureus, a key driver of AD flares.
Biofilm Disruption: Beneficial bacteria can penetrate and disrupt pathogenic biofilms on the skin surface.

3. Barrier Restoration (The Structural Effect):

Upregulation of Tight Junctions: Probiotics and their metabolites (postbiotics like short-chain fatty acids) stimulate the expression of filaggrin, claudin, and occludin—proteins essential for a sealed, hydrated skin barrier.

Future Prospects in Probiotic Eczema Research

The field is moving beyond generic "probiotics" toward Precision Microbiome Therapeutics.

Genetically Engineered Strains: Bacteria modified to secrete specific anti-inflammatory peptides or filaggrin precursors.
Postbiotics: The use of non-viable bacterial extracts or metabolites (cell-free supernatants) to deliver benefits without the safety risks of live bacteria in immunocompromised patients.
Personalized Skincare: Treatments tailored to a patient's specific skin microbiome "enterotype."

Our company stays at the forefront of these trends, offering services to test not just live bacteria, but also lysates, supernatants, and synbiotics.

Why Partner With Us?

Microbiome Specialization

Unlike generalist CROs, we understand the nuances of working with anaerobes, live bacteria stability, and the specific logistics of microbiome research.

Customized AD Models

We have optimized our eczema mouse models specifically for probiotic testing, establishing baseline data for common probiotic reference strains.

End-to-End Data

We don't just give you a "pass/fail." We provide deep mechanistic insight—connecting gut flora changes to skin barrier improvements.

Potential Applications

Biotech & Pharma Companies: Developing novel Live Biotherapeutic Products (LBPs) for FDA approval.
Cosmeceutical Companies: Formulating probiotic-based topical creams and lotions for sensitive skin.
Functional Food Manufacturers: Creating supplements aimed at pediatric or adult allergic conditions.
Academic Research Groups: Needing outsourced, standardized animal modeling for grant validation.

Your Partner in Microbiome Innovation

The potential for probiotics to treat Eczema is immense, offering a natural, effective alternative to chronic immunosuppression. However, proving efficacy requires rigorous science. As your specialized CRO partner, Creative Biolabs provides the technical expertise, validated models, and detailed insights needed to transform your probiotic strains into market-ready therapeutics.

Ready to start your study? Contact our scientific team today to discuss your project requirements and receive a customized study proposal.

Frequently Asked Questions (FAQs)

Can you test both oral and topical probiotic formulations?

Yes. We have established protocols for oral gavage (to test the gut-skin axis) and topical application (to test direct skin colonization and barrier repair).

Do you offer Germ-Free (GF) mouse models?

Yes, we can perform studies in gnotobiotic (germ-free) mice. This allows us to introduce your specific strain into a "blank slate" to isolate its specific effects on the host immune system without interference from the commensal microbiota.

How long does a typical preclinical efficacy study take?

A standard DNCB-induced AD study typically requires 4–6 weeks, including sensitization, treatment, and analysis. However, the timeline varies based on the specific readouts (e.g., sequencing data analysis may add time).

Can you help with strain safety assessment?

Absolutely. We offer acute toxicity testing, translocation assays (checking if bacteria move to blood/organs), and antibiotic resistance profiling to support regulatory safety filings.

Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Accelerate Eczema Research: Probiotic Solution & CRO Service